COMP <GO>
RXO vs PG // 10Y YIELD & FRED MACRO BETA
RXO Inc. (NYSE) VS. Procter & Gamble Company (The) (NYSE) • 15-METRIC TALLY: RXO 2
— PG 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: RXO
LAST: $27.49 (-0.58%) • MKT CAP: $4.56B
macro-sensitivity
1.09
LAST: $161.57 (+0.61%) • MKT CAP: $372.21B
macro-sensitivity
0.87
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RXO VS. PG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RXO | PG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 51.20% | -10.20 | PG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.90% | 25.40% | -28.30 | PG | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.18% | 3.77% | -3.95 | PG | /fcf-yield <GO> |
| Operating Margin | -1.40% | 24.30% | -25.70 | PG | /operating-margins <GO> |
| Net Profit Margin | -1.70% | 19.00% | -20.70 | PG | /net-margins <GO> |
| Revenue Growth (YoY) | 26.20% | 0.30% | +25.90 | RXO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.65% | -2.65 | PG | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.35 | 5.59 | -2.24 | PG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.50% | +0.70 | PG | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.6 | 62.7 | -6.04 | PG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.09 | 0.87 | +0.22 | RXO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 21.7x | +0.30 | PG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.56B | $372.21B | -$367.65B | PG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RXO REV | PG REV | RXO GROSS % | PG GROSS % | RXO FCF | PG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.74B | $84.28B | 44.0% | 51.2% | -$8.0M | $14.04B |
| FY 2024 | $4.55B | $84.04B | 44.0% | 51.4% | -$57.0M | $16.52B |
| FY 2023 | $3.93B | $82.01B | 44.0% | 44.0% | -$87.7M | $13.16B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RXO // BETA 1.09
PG // BETA 0.87